195 related articles for article (PubMed ID: 10510889)
21. [Diagnosis of prostate cancer by means of the ratio of prostate specific antigen/gamma-seminoprotein (P/S ratio)].
Demura T; Ohyama I; Togashi M; Ohashi N; Chikaraishi T; Hirano T; Koyanagi T
Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):731-7. PubMed ID: 7517468
[TBL] [Abstract][Full Text] [Related]
22. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
[TBL] [Abstract][Full Text] [Related]
24. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
25. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
26. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
27. The clinical utility of measuring total PSA, PSA density, gamma-seminoprotein and gamma-seminoprotein/total PSA in prostate cancer prediction.
Sasaki R; Habuchi T; Sato K; Akao T; Kakinuma H; Zhang LQ; Wang L; Matsuo S; Sasaki S; Ogawa O; Kato T
Jpn J Clin Oncol; 2000 Aug; 30(8):337-42. PubMed ID: 11059338
[TBL] [Abstract][Full Text] [Related]
28. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
29. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
30. [Prostate specific antigen in serum of the patients with prostatic cancer].
Akimoto S; Akakura K; Fuse H; Shimazaki J
Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678
[TBL] [Abstract][Full Text] [Related]
31. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
[TBL] [Abstract][Full Text] [Related]
32. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
33. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
[TBL] [Abstract][Full Text] [Related]
34. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
35. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
36. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
37. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios.
Wymenga LF; Duisterwinkel FJ; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
Scand J Urol Nephrol; 2000 Jun; 34(3):181-7. PubMed ID: 10961472
[TBL] [Abstract][Full Text] [Related]
39. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
40. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]